7038 Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
given concurrently with chemotherapy do not improve patient (pt) outcomes compared with …

LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …

Introduction The epidermal growth factor receptor inhibitor erlotinib is an approved treatment
for chemotherapy-refractory advanced non–small-cell lung cancer (NSCLC). Because …

Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …

Introduction: Epidermal growth factor receptor tyrosine kinase inhibitors given concurrently
with chemotherapy do not improve patient outcomes compared with chemotherapy alone in …

Introduction This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib
administered with two standard chemoradiotherapy regimens for non-small cell lung cancer …

Herein, we present a randomized phase III Italian-Canadian trial named TORCH (Tarceva or
Chemotherapy). In TORCH, we are investigating whether erlotinib as first-line therapy until …

Introduction Erlotinib and pemetrexed have been approved for the second-line and
maintenance treatment of non-small cell lung cancer (NSCLC). With the recommended …

7625 Background: In advanced NSCLC, E and B either as a single agent (E) or in
combination with chemotherapy (B) show improved survival. Combinations of targeted …

Three randomized trials (SATURN, ATLAS and IFCT-GFPC 0502) have demonstrated that
the oral antiepidermal growth factor receptor tyrosine kinase inhibitor erlotinib can improve …